Kornimate/medical-research-clean huggingface dataset:
evaluation of the glucotrack, non-invasive glucose monitoring device

Conditions: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus; Gestational Diabetes

Summary: the purpose of this study is to demonstrate the performance of the glucotrack device (non invasive device) in measuring blood glucose levels

diabetes is a leading cause of death in the western world with medical costs increasing annually. there is no cure for diabetes, and blood glucose monitoring is a key component in diabetes treatment and management. consistently high blood sugar levels can, over time, lead to complications such as blindness, kidney disease, heart disease, and nerve damage.in addition, low blood sugars may lead to immediate dangers. self-monitoring of blood glucose levels is essential to the self-management of diabetes and has become widespread over the past decade. blood glucose determinations are currently done by invasive methods (finger tip pricking), followed by measuring the blood drop characteristics. currently, there is no commercially available reliable non-invasive glucose measurement device that being marketed. the glucotrack, non-invasive device for determining glucose levels based on the simultaneous measurement of three independent orthogonal parameters. the rationale for development of the device is to improve the patient's quality of life by providing a device that is easily used and provides a painless measurement method, thereby leading to higher compliance, and to better managed diabetes

Eligibility criteria:
inclusion criteria: * patients with type 1, type 2, or gestational diabetes * above the age of 10 exclusion criteria: * does not meet inclusion criteria * patients requiring dialysis * participation in other clinical investigations within the previous month. * pregnancy(excluding patients that intend to participate in the gestational group)

Keywords: diabetes blood glucose monitoring non invasive blood glucose monitoring
a study to evaluate the safety and effectiveness of oculeve intranasal lacrimal neurostimulator in participants with dry eye syndrome

Conditions: Dry Eye Syndrome; Keratoconjunctivitis Sicca

Summary: the purpose of this study is to compare acute tear production produced by the oculeve intranasal lacrimal neurostimulator with two control devices in participants with aqueous tear deficiency.

this is a prospective, randomized, controlled, double-masked, multicenter clinical trial in which participants with aqueous tear deficiency will receive three different device applications in a randomized sequence.

Eligibility criteria:
inclusion criteria: * participants with aqueous tear deficiency * literate, able to speak english or spanish, and able to complete questionnaires independently * willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol exclusion criteria: * chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the investigator, may lead to clinically significant increased bleeding * nasal or sinus surgery including nasal cautery or significant trauma * cardiac demand pacemaker, implanted defibrillator or other implanted electronic device * diagnosis of epilepsy * corneal transplant in either or both eyes * participation in any clinical trial with a new active substance or a new device within 30 days of the screening visit * a woman who is pregnant, planning a pregnancy, or nursing at the screening visit
effect of pioglitazone therapy for type 2 diabetes on vision

Conditions: Type 2 Diabetes

Summary: we are studying patients with diabetes who under proper medical care and administer an approved drug. our interest is if this drug has any sideeffect on vision and if this drug may cause swelling of the retina.

to evaluate the safety of pioglitazone treatment for diabetes. recent reports suggest that oral glitazone treatment may cause or exacerbate retinal edema. we hypothesized that glitazone treatment may cause subclinical edema evidenced by increased retinal thickness. we will conduct a double-masked, prospective safety study of 19 subjects undergoing placebo-controlled treatment with pioglitazone. patient treatment consisted of either insulin with placebo or insulin with pioglitazone. the main outcome measures are etdrs visual acuity and retinal thickness measured with optical coherence tomography.

Eligibility criteria:
inclusion criteria: * male or female patients with type 2 diabetes mellitus on insulin therapy, 30-75 years of age with hgb 1c values between 7.5 - 10% and a bmi of \< 40kg/m2. * patients were enrolled if they have been on a stable anti-hypertensive and lipid regimen for 90 days prior to study randomization. * patients must have had the ability to understand the requirements of the study, provide written consent and agree to abide by study requirements. exclusion criteria: * prior treatment with sulfonylurea, or metformin within 21 days before study entry, prior treatment with nsaids, or diuretics within 21 days of screening, serum creatinine levels above 1.5 mg/dl for males or above 1.4 for females or creatinine clearance less than 70 ml/min by cockcroft and gault, or serum albumin levels of less than 2.5 gm/dl. * other exclusion criteria were elevated hepatic enzymes (aspartate aminotransferase or alanine aminotransferase more than 2.5 times upper limit of normal) or uncontrolled or untreated significant pulmonary, neurological condition, or cardiovascular disease, including hypertension, congestive heart failure (specifically new york heart association type iii or iv patients), angina, peripheral vascular disease, or greater than +1 peripheral edema. * furthermore, any patients with any condition that would jeopardize their safety or affect the validity of the trial results were excluded from this study.

Keywords: diabetes
human leukocyte antigen-a*2402-restricted tumor vessel specific peptide vaccination for advanced pancreatic cancer

Conditions: Pancreatic Cancer; Pancreas Neoplasms

Summary: feasibility and efficacy of combined modality intervention using chemotherapeutic agent gemcitabine with anti-angiogenic peptide vaccination targeting vrgfr1 should be determined in case of advanced/inoperable or therapy-resistant pancreatic cancer patients. gemcitabine 1,000mg/m2 bsa will be administered on day1, day8, day15, day29, day36, day43, respectively. hla-a\*2402-restricted vegfr1-derived peptide (vegfr1-a24-1084; sygvllwei) emulsified with montanide isa51 will be subcutaneously injected twice weekly for 8weeks (total 16 doses).

hla-a\*2402-restricted cytotoxic t lymphocyte (ctl) clones were obtained from healthy volunteer donor peripheral blood. these ctl clones showed potent cytotoxicities selectively against vegfr1-expressing target cells in hla-class i-restricted manner.

Eligibility criteria:
inclusion criteria: * heterozygote or homozygote of hla-a\*2402 allele * inoperable or recurrent pancreatic cancer with or without any prior therapy * difficult to continue the prior therapy due to treatment-related toxicities * ecog performance status 0-2 * evaluable primary or metastatic lesion with recist criteria * clearance period from prior therapy more than 4 weeks * life expectancy more than 3 months * laboratory values as follows 2,000/μl\ 100,000/μl ast\<150iu/l alt\<150iu/l total bilirubin\<3.0mg/dl serum creatinine\<3.0mg/dl exclusion criteria: * pregnancy (refusal or inability to use effective contraceptives) * breastfeeding * active or uncontrolled infection * systemic use of corticosteroids or immunosuppressants * uncontrollable brain metastasis and/or meningeal infiltration * unhealed external wound * possibilities of complicated paralytic ileus or interstitial pneumonitis * decision of not eligible determined by principal investigator or attending doctor

Keywords: cancer pancreas advanced peptide vaccination vegfr1 hla gemcitabine ifa cancer of pancreas neoplasms, pancreatic pancreas cancer
efficacy of doxycycline prophylaxis to reduce syphilis in high-risk, hiv-positive msm

Conditions: Syphilis

Summary: this pilot study will investigate the feasibility of conducting a large, randomized trial comparing a structural intervention to contingency management to reduce incident syphilis infections in an especially high risk group: hiv+ men who have sex with men (msm) who have had syphilis twice or more since their hiv diagnosis. subjects will be randomized to receive either qd doxycycline as syphilis prophylaxis or a financial incentive to remain sti free. the investigators will : 1) measure adherence to study visits in both arms; 2) measure adherence to the prophylaxis regimen; 3) measure any changes in risk behaviors among study participants and 4) to the extent possible in a small pilot study of short duration, compare effectiveness of doxycycline with that of a monetary incentive for remaining sti free.


Eligibility criteria:
inclusion criteria: * hiv-infected msm or transgender women who have sex with men * at least two documented and adequately treated episodes of syphilis since hiv diagnosis exclusion criteria: * had a known allergy or intolerance to doxycycline * abused alcohol or other substances which in the opinion of the investigators would jeopardize adherence to study procedures

Keywords: men who have sex with men hiv-positive syphilis contingency management
a single-arm, open-label, phase i study of gk01 for advanced solid tumor

Conditions: Advanced Solid Tumors

Summary: this study is a phase i, open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of gk01 in patients with advanced solid tumors.


Eligibility criteria:
1. ability to understand and sign a written informed consent document； 2. at the date of signing icf, 18 \~70 years old, male or female； 3. histopathological confirmed advanced solid tumor patients who have failed to standard treatment or intolerance with standard treatment； 4. there is at least one resectable tumor lesion that has not received radiation therapy or other local therapies; 5. at least one measurable lesion at baseline per recist version 1.1； 6. the expected survival time is more than 12 weeks; 7. ecog 0-1 points; 8. adequate organ functions

Keywords: efficacy safety pk tils
aron-3 study: international multicentric retrospective study to collect global experiences in the treatment of patients with metastatic pca

Conditions: Prostate Cancer

Summary: study wants to explore real-world data in three distinct settings * patients with metachronous or de novo mcspc treated with adt+arsi or adt+arsi+docetaxel _aron-3s * patients receiving lutetium-177 psma for mcrpc _ aron-3lu * patients treated with parp inhibitors (alone or combined with arsi) for crpc _ aron-3gen


Eligibility criteria:
inclusion criteria: * patients aged \>18y * cytological or histologically confirmed diagnosis of pc * histologically or radiologically confirmed diagnosis of metastatic disease and for aron-3s ▪ treatment with adt + apalutamide or adt + enzalutamide or adt + abiraterone or adt + abiraterone + docetaxel or adt + darolutamide + docetaxel (patients treated with previous docetaxel - chaarted - resulted eligible) for aron-3lu ▪ treatment with luthetium-177-psma therapy for castration resistant pc for aron-3gen * hrd positive status * treatment with parp inhibitors for castration resistant pc. treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide exclusion criteria: * patients without histologically confirmed diagnosis of pc * patients without histologically or radiologically confirmed metastatic disease and for aron-3s ▪ patients treated with doublets or triplets not included in the list reported in the inclusion criteria section for aron-3lu ▪ patients treated with luthetium-177-psma therapy for hormone/castration sensitive pc for aron-3gen * hrd negative status * patients treated with parp inhibitors alone or in combination regimens not included in the aron-3gen study

Keywords: mcspc lutetium-177 psma parp inhibitors adt arsi
emollients in the management of atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to confirm that emollients play a major role in the maintenance therapy after clearing of inflammatory lesions and can reduce occurrence of flares in children with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * age between 2 and 6 years included, * presenting with atopic dermatitis, with at least one duly documented flare treated by corticosteroids within the previous 6 months, and presenting a current flare (objective scoring for atopic dermatitis (scorad score) is \[15-40\] at inclusion), * after treatment of the current flare, patients should have for randomization an objective scorad score \< 15, with xerosis intensity≥ 1 and no subjective signs exclusion criteria: * severe form of atopic dermatitis requiring either systemic corticosteroid treatment and/or antibiotic or antiviral treatment and/or hospitalisation, * primary bacterial, viral, fungal or parasitic skin infection, * ulcerated lesions, acne or rosacea, * dermatological disease other than atopic dermatitis which could interfere with the assessment, * immunosuppression,

Keywords: xerosis dry skin dermatitis eczema emollient corticosteroid flare
turkish version of the kinesthetic and visual imagery questionnaire

Conditions: Image, Body; Healthy; Pain

Summary: imagery is determined with two strategies to mentally simulate the movements: visual and kinesthetic imagery. visual motor imagery (vmi) is associated with spatial coordinates of a movement in the environment and through this speciality vmi applies mainly to the imagery of moving objects or to movement of another person in the imagined environment, although imagine of own movement is also possible. kinesthetic motor imagery depends on dynamic relationship among the individual, the movement and the environment and it should be determined by the nature of the task, the environment and individual characteristics and also requires "feel" the movement. the aim of this study is to translate this questionnaire into turkish and the translation in terms of its internal consistency, test-retest reliability.


Eligibility criteria:
inclusion criteria: * ages between 18-65 years, healthy volunteers, with no limitation in mobility or movement disorder, with no chronic pain exclusion criteria: * refuse to attend to the study, neurological conditions

Keywords: motor imagery kinesthetic imagery reliability turkish version
arterial and end-tidal co2 gradient as a mortality predictor in critical care patients

Conditions: Critical Illness; Ventilation Perfusion Mismatch; Shock; Pulmonary Embolism; Trauma; Copd

Summary: scoring systems (sofa, apache-ii etc.) are used to estimate the mortality rates of patients treated in the intensive care unit. . in the scoring systems used, the disfunction level of the organs of the patients is measured. blood gas analysis is routinely performed in patients whom intubated in the intensive care unit and receiving mechanical ventilation support, and the patient's treatment is optimized according to the results of the examination. the patient's mechanical ventilation settings are regulated by analyzing the partial arterial carbondioxide (paco2) value in the patient's blood gas result. the difference between the paco2 value in the blood gas and the end-tidal carbondioxide (etco2) value measured in the mechanical ventilator is 3-5mmhg in normal healthy people, while this difference is seen more in critical care patients. in critically ill patients in the intensive care unit, there is a greater increase in the difference between paco2 and etco2 in cases where mortality is high, such as global perfusion disorder, shock situations, and massive pulmonary embolism, etc. in this study, it was planned to investigate the use of the difference between the paco2 value in the blood gas taken from the patient and the etco2 value measured in the mechanical ventilator to predict the mortality rate of the patient.


Eligibility criteria:
inclusion criteria: * critical care patients intubated in last 24 hours. exclusion criteria: * patients younger than 18 years old.
a trial of observed long-acting, anti-hiv treatment with a monoclonal ccr5 antibody (pro 140) as an adjunct to a new, optimized, oral antiretroviral regimen in hiv-infected injection drug users with viral rebound and documented poor adherence

Conditions: HIV

Summary: pro 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of pro 140 (anti-ccr5 monoclonal antibody) administered subcutaneously as an adjunct to a new, optimized, oral antiretroviral regimen in hiv-infected injection drug users with viral rebound and documented poor adherence to the previous antiretroviral regimen.


Eligibility criteria:
key inclusion criteria: 1. only r5 virus 2. hiv-1 rna \> 1,000 copies/ml but \< 100,000 copies/ml 3. cd4+ lymphocyte counts \> 100 cells/μl 4. non-prescription recreational drug use within the previous 6 months key exclusion criteria: 1. females who are pregnant (positive blood test), lactating, or breastfeeding, or who plan to become pregnant during the study 2. prior use of any ccr5 entry inhibitors 3. history of any acquired immune deficiency syndrome (aids)-defining illness
a research study of how nnc0174-0833 behaves in chinese volunteers who are normal weight, overweight or with obesity

Conditions: Overweight and Obesity

Summary: the aim of this study is to look at how the study medicine behaves in participants body and how it is removed from their body. the study compares three different doses of the study medicine in chinese healthy men. participant will either get 0.3 mg, 0.9 mg or 1.8 mg nnc0174-0833 which dose participant get is decided by chance. nnc0174-0833 is a new medicine and has not been approved by the center for drug evaluation. we are testing the study medicine to make a medicine that can help people lose weight. participant will get 1 injection by a study nurse or doctor at the clinic. the injection will be with a needle in a skin fold in the stomach area. the study will last for about 5 months. but participants participation will last about 2 months. participant will have 8 clinic visits with the study staff. one of these visits will be a 7-day, 6-night stay. at all visits, except the information visit, participant will have blood drawn along with other clinical examinations. participants will be asked about their health, medical history and habits including mental health.


Eligibility criteria:
key inclusion criteria * chinese male subject aged 18-55 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) between 20.0 and 39.9 kg/m\^2 (both inclusive) at screening. * body weight between 60.0 and 110.0 kg (both inclusive) at screening. key exclusion criteria * male subject who is not sexually abstinent or surgically sterilised (vasectomy) or who or whose partner(s) is not willing to use highly effective contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial'). * any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
early genomic testing for inherited bleeding disorders

Conditions: Bleeding Disorder

Summary: the investigators aim to test the introduction of genomic testing early in the diagnostic pathway for inherited bleeding disorders in patients who have not received a diagnosis after first-line testing. the goal of this clinical trial is to test the introduction of genomic testing early in the diagnostic pathway for patients referred to hematology for a suspected inherited bleeding disorder. the main questions it aims to answer are: 1. does adding early genomic testing increase the number of patients who are diagnosed? 2. does adding early genomic testing decrease the overall time to diagnosis? 3. is it cost-effective to include early genomic testing in the diagnostic pathway? the investigators will compare with a control group of participants who are receiving standard care (no early genomic testing). participants will randomized to a standardized diagnostic testing plus early genomic testing group or to the standardized diagnostic testing group only (with the possibility of being offered genomic testing after 1 year in the study).

with the current standardized diagnostic testing process up to 50% of people referred with significant bleeding symptoms will be classified as bleeding disorder of unknown cause (bduc), defined as those with a positive bleeding score but in whom all current diagnostic test results are repeatedly normal. incorporating genomic testing early in the diagnostic pathway could significantly improve diagnostic yield, reduce diagnostic delay, alleviate patient anxiety, and allow for more prompt symptom recognition and targeted treatment.

Eligibility criteria:
inclusion criteria: * new patient referred for abnormal bleeding. * hemostasis expert clinician determined abnormal bleeding history and family history of bleeding * or no family history of bleeding but hemostasis expert clinician determined severe bleeding history. exclusion criteria: * prior diagnosis of an inherited bleeding disorder. * acquired cause of bleeding (i.e., medication known to cause bleeding, significant renal or hepatic disease)

Keywords: blood coagulation disorders bleeding disorder
feasibility and impact of resistance training for sarcopenic dysphagia

Conditions: Sarcopenia; Dysphagia

Summary: the purpose of the study is to test and optimize the feasibility of an activity-based resistance training program for patients with sarcopenic dysphagia. the study is a feasibility study designed as a multiple-case study with quantitative and qualitative data sources related to a number of feasibility outcomes and clinical outcomes during and after the intervention. participants are 15 patients\> 65 years of age are referred for dysphagia assessment by an occupational therapist (patients may be admitted to several different wards (endocrinology, pulmonary medicine, infectious medicine, gastrology). the intervention is offered during hospitalization and after discharge for a maximum of 12 weeks.


Eligibility criteria:
inclusion criteria: * speaks and understand danish language, and able to provide written informed consent for participation * dysphagia verified by a gugging swallowing screen * generalized sarcopenia determined by a danish version of the questionnaire sarc-f * sarcopenia of the swallowing mechanism indicated by reduced tongue strength measured with the iowa oral performance instrument exclusion criteria: * dysphagia related to the esophagus * psychiatric diagnosis * neurodegenerative disease or * needs palliative care * admitted to hospital from a nursing home.

Keywords: dysphagia sarcopenia resistance training task-oriented skill-based